학술논문
Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer
이용수 0
- 영문명
- Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer
- 발행기관
- 대한방사선종양학회
- 저자명
- Byoung Hyuck Kim Jae Sik Kim Hak Jae Kim
- 간행물 정보
- 『대한방사선종양학회지』제41권 제3호, 144~153쪽, 전체 10쪽
- 주제분류
- 의약학 > 종양학
- 파일형태
- 발행일자
- 2023.09.30
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Despite conventionally applied postoperative radiotherapy (PORT) in pathological N2 (pN2) stage non-small cell lung cancer (NSCLC) considering high locoregional recurrence, its survival benefit has been a continuous topic of debate. Although several randomized clinical trials have been conducted, many of them have been withdrawn or analyzed without statistical significance due to slow accrual, making it difficult to determine the efficacy of PORT. Recently, the results of large-scale randomized clinical trials have been published, which showed some improvement in disease-free survival with PORT, but finally had no impact on overall survival. Based on these results, it was expected that the debate over PORT in pN2 patients with NSCLC would come to an end. However, since pN2 patients have different clinicopathologic features, it has become more important to carefully select the patient population who will benefit from PORT. In addition, given the development of systemic treatments such as molecular-targeted therapy and immunotherapy, it is crucial to evaluate whether there is any benefit to PORT in the midst of these recent changes. Therefore, determining the optimal treatment approach for NSCLC pN2 patients remains a complex issue that requires further research and evaluation.
목차
Introduction
Historical Perspective on PORT for N2 Stage NSCLC
Recent Results of Representative RCTs on PORT for N2 Stage NSCLC
Current Guidelines and Recommendations on PORT for N2 Stage NSCLC
Factors Affecting the Choice of PORT for N2 Stage NSCLC: Implications for Patient Selection
Ongoing Trials, Future Directions, and Conclusions
Statement of Ethics
Conflict of Interest
Funding
Author Contributions
Data Availability Statement
References
해당간행물 수록 논문
- Bleeding metastasis of renal cell cancer to anal canal treated with radiation
- Developing prompts from large language model for extracting clinical information from pathology and ultrasound reports in breast cancer
- Outcome of dose-escalated intensity-modulated radiotherapy for limited disease small cell lung cancer
- Feasibility of artificial intelligence-driven interfractional monitoring of organ changes by mega-voltage computed tomography in intensity-modulated radiotherapy of prostate cancer
- Comparison between 1-week and 2-week palliative radiotherapy courses for superior vena cava syndrome
- Application of surface-guided radiation therapy in prostate cancer: comparative analysis of differences with skin marking-guided patient setup
- Clinical outcomes of radical radiotherapy for pulmonary sarcomatoid carcinoma
- Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer
- Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer
- Has the growing evidence of radiotherapy for hepatocellular carcinoma increased the use of radiotherapy in elderly patients?
참고문헌
관련논문
의약학 > 종양학분야 BEST
- 방사선 치료에 내성이 유도된 두경부 편평세포암에 대한 종양살상 헤르페스 바이러스의 유전자 치료 효과
- 식도암에서 근치적 절제술 후 방사선치료의 역할
- 두경부암에서 면역회피 기전과 면역항암제 치료
의약학 > 종양학분야 NEW
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck
- Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!